Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITd frontline therapy in transplant-ineligible multiple myeloma
ChiCTR2000040718Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib, thalidomide and dexamethasone in multiple myeloma (MM), sponsored by Peking University People's Hospital. Primary endpoints: 2-year VGPR or better rate and Overall response rate. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
ixazomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000040718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040718.